- ►annals.org [PDF] VV McLaughlin, DE Genthner, MM Panella, … - Annals of internal …, 1999 - Am Coll Physicians Vallerie V. McLaughlin, MD; Diane E. Genthner, RN, BSN; Maureen M. Panella, RN, BSN; Dina
M. Hess, RN; and Stuart Rich, MD ... Background: Treatment of patients with secondary pul-
monary hypertension has been unsatisfactory. Objective: To describe exercise capacity, ... Cited by 203 - Related articles - BL Direct - All 4 versions
PC Kuo, LB Johnson, JS Plotkin, CD Howell, ST … - Transplantation, 1997 - journals.lww.com The association of pulmonary hypertension with portal hypertension, also called portopulmonary
hypertension (PPHTN), is a known complication of chronic liver disease. Previously, the presence
of PPHTN was considered to be a contraindication to orthotopic liver transplantation ... Cited by 166 - Related articles - BL Direct - All 4 versions
- ►ersj.org.uk [PDF] M Humbert, O Sanchez, M Fartoukh, JL Jagot, C … - European Respiratory …, 1999 - ersj.org.uk Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary
to connective tissue diseases: results of a pilot study. M. Humbert, O. Sanchez, M. Fartoukh,
J.-L. Jagot, C. Le Gall, O. Sitbon, F. Parent, G. Simonneau. #ERS Journals Ltd 1999. ... Cited by 95 - Related articles - BL Direct - All 7 versions
- ►annals.org [PDF] DB Badesch, VF Tapson, MD McGoon, BH … - Annals of Internal …, 2000 - Am Coll Physicians David B. Badesch, MD; Victor F. Tapson, MD; Michael D. McGoon, MD; Bruce H. Brundage,
MD; Lewis J. Rubin, MD; Fredrick M. Wigley, MD; Stuart Rich, MD; Robyn J. Barst, MD; Pamela
S. Barrett, PharmD; Kenneth M. Kral, MS; Maria M. Jöbsis, BA; James E. Loyd, MD; ... Cited by 659 - Related articles - BL Direct - All 6 versions
MJ Krowka, RP Frantz, MD McGoon, C Severson, … - Hepatology, 1999 - interscience.wiley.com Pulmonary hypertension associated with increased pulmonary vascular resistance (PVR) and
occurring in the setting of portal hypertension is referred to as portopulmonary hypertension.
Intravenous epoprostenol (prostacyclin) is a potent pulmonary and systemic vasodilator ... Cited by 145 - Related articles - BL Direct - All 6 versions
IM Robbins, SP Gaine, R Schilz, VF Tapson, LJ … - Chest, 2000 - chestjournal.chestpubs.org * From the Center for Lung Research, Department of Medicine (Drs. Robbins and Loyd), Vanderbilt
University School of Medicine, Nashville, TN; Division of Pulmonary and Critical Care (Dr.
Gaine), University of Maryland School of Medicine, Baltimore, MD; Division of Pulmonary ... Cited by 83 - Related articles - BL Direct - All 8 versions
- ►171.66.122.149 RV Aguilar, HW Farber - American journal of respiratory and critical …, 2000 - 171.66.122.149 Although HIV-associated pulmonary hypertension and primary pulmonary hypertension
(PPH) are clinically and histologically similar, treatment options for the former are limited. Treatment
with calcium channel blockers (CCB), proven to be beneficial in a subset of patients with ... Cited by 107 - Related articles - BL Direct - All 7 versions
- ►onlinejacc.org S Rich, VV McLaughlin - Journal of the American College of Cardiology, 1999 - Elsevier Patients were treated for 39 ± 20 months, resulting in a 71% reduction in pulmonary vascular
resistance compared to baseline. At the time of their most recent evaluation their cardiac outputs
were increased to 10.1 ± 2.3 liter/min. The patients underwent a 39% dose reduction ... Cited by 129 - Related articles - BL Direct - All 12 versions
- ►bmj.com T Higenbottam, AY Butt, A McMahon, R … - British Medical …, 1998 - heart.bmj.com Despite its rarity 1 and the effectiveness of treatment with continuous intravenous
prostaglandin, 2 many patients with primary pulmonary hypertension remain untreated. This
reflects concern about the cost of the drug 3 and uncertainty over the selection criteria for ... Cited by 143 - Related articles - BL Direct - All 10 versions
